Neuroprotective effects of estrogen in CNS injuries: insights from animal models

References

• Vrtačnik P, Ostanek B, Mencej-Bedrač S, Marc J. The many faces of estrogen signaling. Biochem Med (Zagreb). 2014;24(3):329–342.
   PubMed Web of Science ®Google Scholar
• Sribnick EA, Ray SK, Banik NL. Estrogen as a multi-active neuroprotective agent in traumatic injuries. Neurochem Res. 2004;29(11):2007–2014.
   Web of Science ®Google Scholar
• Chakrabarti M, Das A, Samantaray S, Smith JA, Banik NL, Haque A, Ray SK. Molecular mechanisms of estrogen for neuroprotection in spinal cord injury and traumatic brain injury. Rev Neurosci. 2016;27(3):271–281.
   PubMed Web of Science ®Google Scholar
• Samantaray S, Das A, Matzelle DC, et al. Administration of low dose estrogen attenuates gliosis and protects neurons in acute spinal cord injury in rats. J Neurochem. 2016;136(5):1064–1073.
   Web of Science ®Google Scholar
• Simpson E, Rubin G, Clyne C, et al. The role of local estrogen biosynthesis in males and females. Trends Endocrinol Metab. 2000;11(5):184–188.
   PubMed Web of Science ®Google Scholar
• Siddiqui AN, Siddiqui N, Khan RA, et al. Neuroprotective role of steroidal sex hormones: an overview. CNS Neurosci Ther. 2016;22(5):342–350.
   Web of Science ®Google Scholar
• Marin R, Guerra B, Alonso R, Ramírez CM, Díaz M. Estrogen activates classical and alternative mechanisms to orchestrate neuroprotection. Curr Neurovasc Res. 2005;2(4):287–301.
   Web of Science ®Google Scholar
• Chakrabarti M, Haque A, Banik NL, Nagarkatti P, Nagarkatti M, Ray SK. Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration. Brain Res Bull. 2014;109:22–31.
   Web of Science ®Google Scholar
• Ray SK, Samantaray S, Banik NL. Future directions for using estrogen receptor agonists in the treatment of acute and chronic spinal cord injury. Neural Regen Res. 2016;11(9):1418–1419. Erratum in: Neural Regen Res. 2017;12(2):266.
   Web of Science ®Google Scholar
• Cox A, Varma A, Barry J, Vertegel A, Banik N. Nanoparticle estrogen in rat spinal cord injury elicits rapid anti-inflammatory effects in plasma, cerebrospinal fluid, and tissue. J Neurotrauma. 2015;32(18):1413–1421.
   Web of Science ®Google Scholar
• Lee JY, Choi HY, Na WH, Ju BG, Yune TY. 17β-estradiol inhibits MMP-9 and SUR1/TrpM4 expression and activation and thereby attenuates BSCB disruption/hemorrhage after spinal cord injury in male rats. Endocrinology. 2015;156(5):1838–1850.
   Web of Science ®Google Scholar
• Han D, Scott EL, Dong Y, Raz L, Wang R, Zhang Q. Attenuation of mitochondrial and nuclear p38α signaling: a novel mechanism of estrogen neuroprotection in cerebral ischemia. Mol Cell Endocrinol. 2015;400:21–31.
   Web of Science ®Google Scholar
• Soltani Z, Khaksari M, Shahrokhi N, et al. Effect of estrogen and/or progesterone administration on traumatic brain injury-caused brain edema: the changes of aquaporin-4 and interleukin-6. J Physiol Biochem. 2016;72(1):33–44.
   Web of Science ®Google Scholar
• Dubal DB, Zhu H, Yu J, et al. Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci U S A. 2001;98(4):1952–1957.
   Web of Science ®Google Scholar
• Mosquera L, Colón JM, Santiago JM, et al. Tamoxifen and estradiol improved locomotor function and increased spared tissue in rats after spinal cord injury: their antioxidant effect and role of estrogen receptor alpha. Brain Res. 2014;1561:11–22.
   Web of Science ®Google Scholar
• Sampei K, Goto S, Alkayed NJ, et al. Stroke in estrogen receptor-alpha-deficient mice. Stroke. 2000;31(3):738–743.
   PubMed Web of Science ®Google Scholar
• Shughrue PJ, Lane MV, Merchenthaler I. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol. 1997;388(4):507–525.
   PubMed Web of Science ®Google Scholar
• Hu R, Sun H, Zhang Q, et al. G-protein coupled estrogen receptor 1 mediated estrogenic neuroprotection against spinal cord injury. Crit Care Med. 2012;40(12):3230–3237.
   Web of Science ®Google Scholar
• Islamov RR, Hendricks WA, Katwa LC, et al. Effect of 17 beta-estradiol on gene expression in lumbar spinal cord following sciatic nerve crush injury in ovariectomized mice. Brain Res. 2003;966(1):65–75.
   Web of Science ®Google Scholar
• Zhu C, Wang S, Wang B, et al. 17β-Estradiol up-regulates Nrf2 via PI3K/AKT and estrogen receptor signaling pathways to suppress light-induced degeneration in rat retina. Neuroscience. 2015;304:328–339.
   Web of Science ®Google Scholar
• Culmsee C, Vedder H, Ravati A, et al. Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism. J Cereb Blood Flow Metab. 1999;19(11):1263–1269.
   Web of Science ®Google Scholar
• Sugishita K, Li F, Su Z, Barry WH. Anti-oxidant effects of estrogen reduce [Ca2+ ]i during metabolic inhibition. J Mol Cell Cardiol. 2003;35(3):331–336.
   Google Scholar
• Qian M, Engler-Chiurazzi EB, Lewis SE, Rath NP, Simpkins JW, Covey DF. Structure-activity studies of non-steroid analogs structurally-related to neuroprotective estrogens. Org Biomol Chem. 2016;14(41):9790–9805.
   Web of Science ®Google Scholar
• Prokai-Tatrai K, Perjesi P, Zharikova AD, Perez EJ, Liu R, Simpkins JW. Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci U S A. 2003;100(20):11741–11746.
   Web of Science ®Google Scholar
• Grimm A, Schmitt K, Lang UE, Mensah-Nyagan AG, Eckert A. Improvement of neuronal bioenergetics by neurosteroids: implications for age-related neurodegenerative disorders. Biochim Biophys Acta. 2014;1842(12 Pt A):2427–2438.
   Web of Science ®Google Scholar
• Fiedler IG, Laud PW, Maiman DJ, Apple DF Jr. Economics of managed care in spinal cord injury. Arch Phys Med Rehabil. 1999;80:1441–1449.
   PubMed Web of Science ®Google Scholar
• Selvarajah S, Hammond ER, Haider AH, et al. The burden of acute traumatic spinal cord injury among adults in the United States: an update. J Neurotrauma. 2014;31(3):228–238.
   PubMed Web of Science ®Google Scholar
• Mahabaleshwarkar R, Khanna R. National hospitalization burden associated with spinal cord injuries in the United States. Spinal Cord. 2014;52(2):139–144.
   PubMed Web of Science ®Google Scholar
• Dismuke CE, Egede LE, Saunders L, Krause JS. Diabetes increases financial burden of individuals with traumatic spinal cord injury (TSCI). Spinal Cord. 2015;53(2):135–138.
   Web of Science ®Google Scholar
• DeVivo MJ. Causes and costs of spinal cord injury in the United States. Spinal Cord. 1997;35(12):809–813.
   PubMed Web of Science ®Google Scholar
• Eastwood EA, Hagglund KJ, Ragnarsson KT, Gordon WA, Marino RJ. Medical rehabilitation length of stay and outcomes for persons with traumatic spinal cord injury– 1990–1997. Arch Phys Med Rehabil. 1999;80:1457–1463.
   Google Scholar
• Pereira JE, Costa LM, Cabrita AM, et al. Methylprednisolone fails to improve functional and histological outcome following spinal cord injury in rats. Exp Neurol. 2009;220(1):71–81.
   Web of Science ®Google Scholar
• Wu Y, Hou J, Collier L, et al. The administration of high-dose methylprednisolone for 24 hour reduced muscle size and increased atrophy-related gene expression in spinal cord-injured rats. Spinal Cord. 2011;49(8):867–873.
   Web of Science ®Google Scholar
• Samantaray S, Das A, Matzelle DC, et al. Administration of low dose estrogen attenuates persistent inflammation, promotes angiogenesis, and improves locomotor function following chronic spinal cord injury in rats. J Neurochem. 2016;137(4):604–617.
   PubMed Web of Science ®Google Scholar
• Kim YH, Ha KY, Kim SI. Spinal cord injury and related clinical trials. Clin Orthop Surg. 2017;9(1):1–9.
   PubMed Web of Science ®Google Scholar
• Griesbach GS, Kreber LA, Harrington D, Ashley MJ. Post-acute traumatic brain injury rehabilitation: effects on outcome measures and life care costs. J Neurotrauma. 2015;32(10):704–711.
   Web of Science ®Google Scholar
• Dismuke CE, Walker RJ, Egede LE. utilization and cost of health services in individuals with traumatic brain injury. Glob J Health Sci. 2015;7(6):156–169.
   Google Scholar
• Schiraldi M, Patil CG, Mukherjee D, et al. Effect of insurance and racial disparities on outcomes in traumatic brain injury. J Neurol Surg A Cent Eur Neurosurg. 2015;76(3):224–232.
   PubMedGoogle Scholar
• Spitz G, McKenzie D, Attwood D, Ponsford JL. Cost prediction following traumatic brain injury: model development and validation. J Neurol Neurosurg Psychiatry. 2016;87(2):173–180.
   Web of Science ®Google Scholar
• Wei W, Sambamoorthi U, Crystal S, Findley PA. Mental illness, traumatic brain injury, and Medicaid expenditures. Arch Phys Med Rehabil. 2005;86(5):905–911.
   Web of Science ®Google Scholar
• Alali AS, Burton K, Fowler RA, et al. Economic evaluations in the diagnosis and management of traumatic brain injury: a systematic review and analysis of quality. Value Health. 2015;18(5):721–734.
   Web of Science ®Google Scholar
• Diaz-Arrastia R, Kochanek PM, Bergold P, et al. Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup. J Neurotrauma. 2014;31(2):135–158.
   PubMed Web of Science ®Google Scholar
• Margulies S, Hicks R; Combination Therapies for Traumatic Brain Injury Workshop Leaders. Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma. 2009;26(6):925–939.
   Google Scholar
• Flynn RW, MacWalter RS, Doney AS. The cost of cerebral ischaemia. Neuropharmacology. 2008;55(3):250–256.
   PubMed Web of Science ®Google Scholar
• Lewandowski C, Barsan W. Treatment of acute ischemic stroke. Ann Emerg Med. 2001;37(2):202–216.
   PubMed Web of Science ®Google Scholar
• Goyal N, Male S, Al Wafai A, Bellamkonda S, Zand R. Cost burden of stroke mimics and transient ischemic attack after intravenous tissue plasminogen activator treatment. J Stroke Cerebrovasc Dis. 2015;24(4):828–833.
   Web of Science ®Google Scholar
• Brinjikji W, Rabinstein AA, Cloft HJ. Hospitalization costs for acute ischemic stroke patients treated with intravenous thrombolysis in the United States are substantially higher than medicare payments. Stroke. 2012;43(4):1131–1133.
   Web of Science ®Google Scholar
• Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health. 2002;5(2):82–97.
   Web of Science ®Google Scholar
• Dion JE. Management of ischemic stroke in the next decade: stroke centers of excellence. J Vasc Interv Radiol. 2004;15(1 Pt 2):S133–S141.
   Google Scholar
• Chen HS, Qi SH, Shen JG. One-Compound-Multi-Target: combination prospect of natural compounds with thrombolytic therapy in acute ischemic stroke. Curr Neuropharmacol. 2017;15(1):134–156.
   PubMed Web of Science ®Google Scholar
• de Ridder IR, Fransen PS, Beumer D, et al. Is intra-arterial treatment for acute ischemic stroke less effective in women than in men? Interv Neurol. 2016;5(3–4):174–178.
   PubMedGoogle Scholar
• Ray SK, Samantaray S, Smith JA, Matzelle DD, Das A, Banik NL. Inhibition of cysteine proteases in acute and chronic spinal cord injury. Neurotherapeutics. 2011;8(2):180–186.
   Web of Science ®Google Scholar
• Sámano C, Kaur J, Nistri A. A study of methylprednisolone neuroprotection against acute injury to the rat spinal cord in vitro. Neuroscience. 2016;315:136–149.
   PubMed Web of Science ®Google Scholar
• MacMahon PJ, Huang AJ, Palmer WE. Spine injectables: What is the safest cocktail? AJR Am J Roentgenol. 2016;207(3):526–533.
   Web of Science ®Google Scholar
• Farooque M, Suo Z, Arnold PM, et al. Gender-related differences in recovery of locomotor function after spinal cord injury in mice. Spinal Cord. 2006;44(3):182–187.
   PubMed Web of Science ®Google Scholar
• Letaif OB, Cristante AF, Barros Filho TE, et al. Effects of estrogen on functional and neurological recovery after spinal cord injury: an experimental study with rats. Clinics (Sao Paulo). 2015;70(10):700–705.
   Web of Science ®Google Scholar
• Sribnick EA, Wingrave JM, Matzelle DD, Wilford GG, Ray SK, Banik NL. Estrogen attenuated markers of inflammation and decreased lesion volume in acute spinal cord injury in rats. J Neurosci Res. 2005;82(2):283–293.
   PubMed Web of Science ®Google Scholar
• Sribnick EA, Samantaray S, Das A, et al. Postinjury estrogen treatment of chronic spinal cord injury improves locomotor function in rats. J Neurosci Res. 2010;88(8):1738–1750.
   Web of Science ®Google Scholar
• Hendriks AE, Laven JS, Valkenburg O, et al. Fertility and ovarian function in high-dose estrogen-treated tall women. J Clin Endocrinol Metab. 2011;96(4):1098–1105.
   Web of Science ®Google Scholar
• Hendriks AE, Drop SL, Laven JS, Boot AM. Fertility of tall girls treated with high-dose estrogen, a dose-response relationship. J Clin Endocrinol Metab. 2012;97(9):3107–3114.
   Web of Science ®Google Scholar
• Benyi E, Kieler H, Linder M, et al. Risks of malignant and non-malignant tumors in tall women treated with high-dose estrogen during adolescence. Horm Res Paediatr. 2014;82(2):89–96.
   Web of Science ®Google Scholar
• Wibowo E, Schellhammer P, Wassersug RJ. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol. 2011;185(1):17–23.
   PubMed Web of Science ®Google Scholar
• Blank EW, Wong PY, Lakshmanaswamy R, Guzman R, Nandi S. Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. Proc Natl Acad Sci U S A. 2008;105(9):3527–3532.
   Web of Science ®Google Scholar
• Tohda C, Kuboyama T. Current and future therapeutic strategies for functional repair of spinal cord injury. Pharmacol Ther. 2011;132(1):57–71.
   PubMed Web of Science ®Google Scholar
• Chakrabarti M, Banik NL, Ray SK. miR-7–1 potentiated estrogen receptor agonists for functional neuroprotection in VSC4, 1 motoneurons. Neuroscience. 2014;256:322–333.
   Web of Science ®Google Scholar
• Naderi V, Khaksari M, Abbasi R, Maghool F. Estrogen provides neuroprotection against brain edema and blood brain barrier disruption through both estrogen receptors α and β following traumatic brain injury. Iran J Basic Med Sci. 2015;18(2):138–144.
   Web of Science ®Google Scholar
• Zlotnik A, Leibowitz A, Gurevich B, et al. Effect of estrogens on blood glutamate levels in relation to neurological outcome after TBI in male rats. Intensive Care Med. 2012;38(1):137–144.
   PubMed Web of Science ®Google Scholar
• Khaksari M, Abbasloo E, Dehghan F, Soltani Z, Asadikaram G. The brain cytokine levels are modulated by estrogen following traumatic brain injury: Which estrogen receptor serves as modulator? Int Immunopharmacol. 2015;28(1):279–287.
   Web of Science ®Google Scholar
• Soltani Z, Khaksari M, Jafari E, Iranpour M, Shahrokhi N. Is genistein neuroprotective in traumatic brain injury? Physiol Behav. 2015;152(Pt A):26–31.
   Google Scholar
• Kim H, Cam-Etoz B, Zhai G, Hubbard WJ, Zinn KR, Chaudry IH. Salutary effects of estrogen sulfate for traumatic brain injury. J Neurotrauma. 2015;32(16):1210–1216.
   Web of Science ®Google Scholar
• Schaible EV, Windschügl J, Bobkiewicz W, et al. 2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIF-1α response after traumatic brain injury in mice. J Neurochem. 2014;129(6):940–954.
   Web of Science ®Google Scholar
• Gorska M, Zmijewski MA, Kuban-Jankowska A, Wnuk M, Rzeszutek I, Wozniak M. Neuronal nitric oxide synthase-mediated genotoxicity of 2-methoxyestradiol in hippocampal HT22 cell line. Mol Neurobiol. 2016;53(7):5030–5040.
   Web of Science ®Google Scholar
• Nuñez JL, McCarthy MM. Estradiol exacerbates hippocampal damage in a model of preterm infant brain injury. Endocrinology. 2003;144(6):2350–2359.
   PubMed Web of Science ®Google Scholar
• Lamprecht MR, Morrison B 3rd. A combination therapy of 17β-estradiol and memantine is more neuroprotective than monotherapies in an organotypic brain slice culture model of traumatic brain injury. J Neurotrauma. 2015;32(17):1361–1368.
   Web of Science ®Google Scholar
• Carpenter RS, Iwuchukwu I, Hinkson CL, et al. High-dose estrogen treatment at reperfusion reduces lesion volume and accelerates recovery of sensorimotor function after experimental ischemic stroke. Brain Res. 2016;1639:200–213.
   Web of Science ®Google Scholar
• Hoffmann S, Beyer C, Zendedel A. Comparative analysis of gonadal steroid-mediated neuroprotection after transient focal ischemia in rats: route of application and substrate composition. J Mol Neurosci. 2015;56(1):12–16.
   Web of Science ®Google Scholar
• Castelló-Ruiz M, Torregrosa G, Burguete MC, et al. The selective estrogen receptor modulator, bazedoxifene, reduces ischemic brain damage in male rat. Neurosci Lett. 2014;575:53–57.
   Web of Science ®Google Scholar
• Lamprecht MR, Morrison B 3rd. GPR30 activation is neither necessary nor sufficient for acute neuroprotection by 17β-estradiol after an ischemic injury in organotypic hippocampal slice cultures. Brain Res. 2014;1563:131–137.
   Web of Science ®Google Scholar
• Zhang QG, Wang R, Tang H, et al. Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus. Mol Cell Endocrinol. 2014;389(1–2):84–91.
   PubMed Web of Science ®Google Scholar
• Madinier A, Wieloch T, Olsson R, Ruscher K. Impact of estrogen receptor beta activation on functional recovery after experimental stroke. Behav Brain Res. 2014;261:282–288.
   Web of Science ®Google Scholar
• Desjardins GC, Brawer JR, Beaudet A. Estradiol is selectively neurotoxic to hypothalamic beta-endorphin neurons. Endocrinology. 1993;132(1):86–93.
   Web of Science ®Google Scholar
• Selvamani A, Sohrabji F. The neurotoxic effects of estrogen on ischemic stroke in older female rats is associated with age-dependent loss of insulin-like growth factor-1. J Neurosci. 2010;30(20):6852–6861.
   Web of Science ®Google Scholar
• Liu R, Liu Q, He S, Simpkins JW, Yang SH. Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke. J Pharmacol Exp Ther. 2010;332(3):1006–1012.
   Web of Science ®Google Scholar
• Lee JS, Kim YK, Yang H, Kang HY, Ahn C, Jeung EB. Two faces of the estrogen metabolite 2-methoxyestradiol in vitro and in vivo. Mol Med Rep. 2015;12(4):5375–5382.
   Web of Science ®Google Scholar
• Chen SH, Yeh CH, Lin MY, et al. Premarin improves outcomes of spinal cord injury in male rats through stimulating both angiogenesis and neurogenesis. Crit Care Med. 2010;38(10):2043–2051.
   Web of Science ®Google Scholar
• Chen SH, Chang CY, Chang HK, et al. Premarin stimulates estrogen receptor-alpha to protect against traumatic brain injury in male rats. Crit Care Med. 2009;37(12):3097–3106.
   Web of Science ®Google Scholar
• Wang YF, Fan ZK, Cao Y, Yu DS, Zhang YQ, Wang YS. 2-Methoxyestradiol inhibits the up-regulation of AQP4 and AQP1 expression after spinal cord injury. Brain Res. 2011;1370:220–226.
   Web of Science ®Google Scholar
• Chen W, Jadhav V, Tang J, Zhang JH. HIF-1 alpha inhibition ameliorates neonatal brain damage after hypoxic-ischemic injury. Acta Neurochir Suppl. 2008;102:395–399.
   Google Scholar
• Duncan GS, Brenner D, Tusche MW, et al. 2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation. Proc Natl Acad Sci U S A. 2012;109(51):21034–21039.
   Web of Science ®Google Scholar
• Schaufelberger SA, Rosselli M, Barchiesi F, Gillespie DG, Jackson EK, Dubey RK. 2-Methoxyestradiol, an endogenous 17β-estradiol metabolite, inhibits microglial proliferation and activation via an estrogen receptor-independent mechanism. Am J Physiol Endocrinol Metab. 2016;310(5):E313–E322.
   Web of Science ®Google Scholar
• James J, Murry DJ, Treston AM, et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs. 2007;25(1):41–48.
   Web of Science ®Google Scholar
• Jennings BL, Moore JA, Pingili AK, et al. Disruption of the cytochrome P-450 1B1 gene exacerbates renal dysfunction and damage associated with angiotensin II-induced hypertension in female mice. Am J Physiol Renal Physiol. 2015;308(9):F981–F992.
   Web of Science ®Google Scholar
• Shand FH, Langenbach SY, Keenan CR, Ma SP, Wheaton BJ, Schuliga MJ, Ziogas J, Stewart AG. In vitro and in vivo evidence for anti-inflammatory properties of 2-methoxyestradiol. J Pharmacol Exp Ther. 2011;336(3):962–972.
   Web of Science ®Google Scholar
• Tofovic SP, Salah EM, Dubey RK, Melhem MF, Jackson EK. Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol. 2005;46:25–35.
   PubMed Web of Science ®Google Scholar
• Dubey RK, Jackson EK. Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol Metab. 2009;20(8):374–379.
   Web of Science ®Google Scholar
• Engler-Chiurazzi EB, Brown CM, Povroznik JM, Simpkins JW. Estrogens as neuroprotectants: estrogenic actions in the context of cognitive aging and brain injury. Prog Neurobiol. 2016 Feb 15. pii: S0301–0082(15)30,063–0.
   Web of Science ®Google Scholar
• Green PS, Simpkins JW. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci. 2000;18(4–5):347–358.
   PubMed Web of Science ®Google Scholar
• Green PS, Yang SH, Simpkins JW. Neuroprotective effects of phenolic A ring oestrogens. Novartis Found Symp. 2000;230:202–213; discussion 213–220.
   Google Scholar
• Littleton-Kearney MT, Ostrowski NL, Cox DA, Rossberg MI, Hurn PD. Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev. 2002;8(3):309–330.
   Google Scholar
• Yi KD, Perez E, Yang S, Liu R, Covey DF, Simpkins JW. The assessment of non-feminizing estrogens for use in neuroprotection. Brain Res. 2011;1379:61–70.
   Web of Science ®Google Scholar
• Petrone AB, Gatson JW, Simpkins JW, Reed MN. Non-feminizing estrogens: a novel neuroprotective therapy. Mol Cell Endocrinol. 2014;389(1–2):40–47.
   Web of Science ®Google Scholar
• Song WO, Chun OK, Hwang I, Shin HS, Kim BG, Kim KS, Lee SY, Shin D, Lee SG. Soy isoflavones as safe functional ingredients. J Med Food. 2007;10(4):571–580.
   PubMed Web of Science ®Google Scholar
• Qian Y, Guan T, Huang M, Cao L, Li Y, Cheng H, Jin H, Yu D. Neuroprotection by the soy isoflavone, genistein, via inhibition of mitochondria-dependent apoptosis pathways and reactive oxygen induced-NF-κB activation in a cerebral ischemia mouse model. Neurochem Int. 2012;60(8):759–767.
   PubMed Web of Science ®Google Scholar
• Prokai-Tatrai K, Perjesi P, Rivera-Portalatin NM, Simpkins JW, Prokai L. Mechanistic investigations on the antioxidant action of a neuroprotective estrogen derivative. Steroids. 2008;73(3):280–288.
   PubMed Web of Science ®Google Scholar
• Sharma HS. Neurotrophic factors in combination: a possible new therapeutic strategy to influence pathophysiology of spinal cord injury and repair mechanisms. Curr Pharm Des. 2007;13(18):1841–1874.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhou CX, Zhang ZJ, Wang LY, Jing ZW, Wang Z. Synergistic mechanism of gene expression and pathways between jasminoidin and ursodeoxycholic acid in treating focal cerebral ischemia-reperfusion injury. CNS Neurosci Ther. 2012;18(8):674–682.
   Web of Science ®Google Scholar